Q-omics provides the consensus-scored GOLGA8CP profile across patient tissues and cancer cell-line models. GOLGA8CP expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GOLGA8CP is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, GOLGA8CP RNA expression shows 5,650 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, BRCA, and STAD as cancer lineages where GOLGA8CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA8CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA8CP survival associations across molecular data types. GOLGA8CP RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA8CP RNA expression–survival associations across cancer types. High GOLGA8CP expression shows unfavorable associations in KIRC, KIRP, UVM, BLCA, MESO and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GOLGA8CP RNA expression.
This table summarizes GOLGA8CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA8CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA8CP shows lower tumor expression in BRCA and higher tumor expression in KIRP and THCA. The BRCA box plot shows higher GOLGA8CP RNA expression in normal versus tumor tissue (log2 FC = −0.002, t-test p = .018).
This table shows molecular features associated with GOLGA8CP in patient tissues and cancer cell lines. In patient samples, GOLGA8CP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
